{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-039248","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.744056+00:00","generated_at":"2026-05-26T01:32:33.793907+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silence Therapeutics extends cash runway into 2027; will require partner for zerlasiran Phase 3","bullets":["Net loss of $45.3M ($0.33 per share) for FY2024, compared to $54.2M loss in FY2023.","Cash, cash equivalents and short-term investments of $147.3M at Dec 31, 2024.","Collaboration revenue $43.1M (up $12.2M YoY); R&D expenses $67.9M (up $11M).","Zerlasiran Phase 3 CVOT will not start without a partner; cash guidance extended into 2027.","Divesiran Phase 2 PV enrollment expected to complete by end-2025; Hansoh Pharma exited collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-039248","json":"https://secwatch.observer/filing/0001193125-25-039248.json","markdown":"https://secwatch.observer/filing/0001193125-25-039248.md","text":"https://secwatch.observer/filing/0001193125-25-039248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525039248/0001193125-25-039248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525039248/d925669d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:32:33.793907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}